Nachrichten zur Biomarin Pharmaceutical Inc. Aktie

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

…

BioMarin Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call Presentation

…

BioMarin Pharmaceutical Aktie trotz wachsender Konkurrenz überverkauft?

St. Petersburg (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von BMO Capital Markets: Raymond James hat die Berichterstattung über BioMarin Pharmaceutical Inc. (ISIN: US09061G1013,…

BioMarin Pharmaceutical: Kursziel reduziert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Sanford C. Bernstein & Co bewerten die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN: 924801,…

BioMarin Pharmaceutical: Kursziel gesenkt

Toronto (www.aktiencheck.de) - Rating-Update: George Farmer, Analyst der Scotiabank, bekräftigt das "sector perform"-Votum für die BioMarin Pharmaceutical-Aktie (ISIN: US09061G1013, WKN: 924801,…

BioMarin Pharmaceutical-Aktienanalyse: Unter Wettbewerbsdruck

Toronto (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung RBC Capital hat das Kursziel für BioMarin Pharmaceutical Inc. (ISIN: US09061G1013,…

BioMarin Pharmaceutical-Aktienanalyse: Ergebnisse von Ascendis Pharma stellen eine neue Herausforderung dar

Charlotte (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von BofA Securities: Aktuelle Situation Jason Zemansky, Analyst von BofA Securities, hat das Kursziel für BioMarin Pharmaceutical…

BioMarin Pharmaceutical-Aktienanalyse: Unsicherheiten über die zukünftige Marktposition von Voxzogo - Neues Kursziel

St. Louis (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Stifel: Aktuelle Situation Die Analysten von Stifel haben das Kursziel für BioMarin Pharmaceutical Inc. (ISIN:…

BioMarin Pharmaceutical-Aktienanalyse: Wells Fargo senkt Kursziel auf 90 USD, bleibt jedoch langfristig positiv

San Francisco (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von Wells Fargo Advisors: Wells Fargo hat das Kursziel für die Aktien von BioMarin Pharmaceutical…

BioMarin Pharmaceutical: A Volatile But Growing Trajectory

…

BioMarin Pharmaceutical-Aktienanalyse: JPMorgan reduziert Kursziel

New York (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von JPMorgan: JPMorgan-Analystin Jessica Fye hat das Kursziel für BioMarin Pharmaceutical (ISIN: US09061G1013, WKN: 924801,…

BioMarin Pharmaceutical: Kursziel 110 USD

New York (www.aktiencheck.de) - Rating-Update: Olivia Brayer, Analystin von Cantor Fitzgerald, stuft die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN:…

BioMarin Pharmaceutical: Kursziel angehoben

Minneapolis (www.aktiencheck.de) - Rating-Update: Die Analysten von Piper Sandler stufen die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN 924801, Ticker-Symbol:…

BioMarin Pharmaceutical: Kursziel gekappt

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist bewerten die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN: 924801, Ticker-Symbol:…

Zacks.com featured highlights include Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo

Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo are part of the Zacks Screen of the Week article.…

BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript

…

BioMarin Pharmaceutical Q2 2024 Earnings Preview

…

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

…

BioMarin Pharmaceutical: Kursziel erhöht

San Francisco (www.aktiencheck.de) - Rating-Update: Die Einschätzung von Mohit Bansal, Analyst von Wells Fargo Advisors, für die Aktie von BioMarin Pharmaceutical…

BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript

…

BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation

…

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the…

GMAB: 3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy…

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

…

BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation

…

BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript

…

Pro Research: Wall Street examines BioMarin Pharmaceuticals prospects By Investing.com

Pro Research: Wall Street examines BioMarin Pharmaceuticals prospects…

Buy These 4 Low-Beta Stocks to Counter Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron…

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

BioMarin Pharmaceutical officer disposes stake worth $1.31M under trading plan

…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

BioMarin Pharmaceutical says CEO Bienaimé to retire, Hardy to take up post

…

BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript

…

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.…

[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Insiderhandel: EVP, Chief Legal Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 983.662$

Davis, George Eric - Vorstand - Tag der Transaktion: 2023-08-08...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 529.740$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-08...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 352.400$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-07...…

Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo....…

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended…

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the…

Biomarin Pharmaceutical Inc. Q2 Profit Increases, beats estimates

WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced earnings for its second quarter that increased from the same period last…

BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program…

dpa-AFX ProFeed